Spine Innovation Gains FDA Clearance for Advanced LOGIC™ Titanium Implant System

Spine Innovation's Breakthrough in Spinal Surgery

Spine Innovation, LLC, a medical device startup, has recently announced that its LOGIC™ Titanium Expandable Interbody System has received FDA 510(k) clearance. This innovative system aims to revolutionize spinal fusion surgery with advanced materials and design technology.

Since its inception in 2013, Spine Innovation has dedicated itself to addressing unmet medical needs in spine surgery by collaborating with leading surgeons from Scripps Health in San Diego, California. The LOGIC™ system represents a significant leap in interbody fusion implants. Utilizing the patented OsteoSync™ Ti, a pure titanium lattice material, this implant has already been successfully used in over 250,000 patients worldwide since its introduction in 2014.

What Sets LOGIC™ Apart?

The LOGIC™ Titanium Implant System is uniquely designed for better surgical outcomes. Its innovative construction features a reduced profile during implantation, enabling it to expand more than double its original size once in place. This design enhancement ensures maximum stability and optimizes bone graft volume, crucial for successful fusion.

In addition, the implant restores disc height and sagittal balance, addressing common issues faced during spinal surgery. With a footprint of 18 mm x 26 mm, it effectively spans the vertebral body while resisting subsidence and expulsion of the implant. What’s more, its previous model, constructed from polyether ether ketone (PEEK), has been a reliable solution in the U.S. for the past decade.

The Future of Spinal Surgery

With FDA clearance secured, Spine Innovation is set to expand the clinical use of the LOGIC™ system across the United States. The company is actively seeking sales and distribution partners to facilitate this growth. As they move forward, they maintain a commitment to providing effective solutions and improving patient outcomes.

For stakeholders in the medical device sector, the advancements represented by the LOGIC™ Titanium Implant System signify a promising future in spinal surgeries. Not only does it incorporate advanced material sciences, but it also reflects a deep understanding of the clinical challenges faced by surgeons and patients alike.

As healthcare providers look for reliable and efficient products to enhance surgical practices, the LOGIC™ system stands out as a prime candidate. The combination of innovative engineering and proven outcomes could set a new benchmark in spinal fusion technology.

For more information about Spine Innovation and the LOGIC™ Titanium Implant System, interested parties can visit their official website or contact representative Morris Bernstein directly for inquiries.

In conclusion, the FDA approval of the LOGIC™ Titanium Expandable Interbody System marks a significant milestone for Spine Innovation and the broader field of spinal surgery. As they continue to push forward, the potential to positively influence countless lives through improved spinal health is more promising than ever.